Hepion Pharmaceuticals Announces Executive Leadership Changes
Ticker: CTRVP · Form: 8-K · Filed: Feb 20, 2024 · CIK: 1583771
| Field | Detail |
|---|---|
| Company | Hepion Pharmaceuticals, Inc. (CTRVP) |
| Form Type | 8-K |
| Filed Date | Feb 20, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, compensatory-arrangements
TL;DR
**Hepion Pharmaceuticals just shook up its executive team and compensation, watch for strategic shifts!**
AI Summary
Hepion Pharmaceuticals, Inc. filed an 8-K on February 20, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. The filing indicates changes in the company's leadership and executive compensation structures. This event is significant for investors as it signals potential shifts in strategic direction or operational management.
Why It Matters
Changes in executive leadership and compensation can significantly impact a company's strategic direction, operational efficiency, and investor confidence, potentially affecting future stock performance.
Risk Assessment
Risk Level: medium — Changes in leadership can introduce uncertainty but also opportunities for new strategic direction.
Key Players & Entities
- Hepion Pharmaceuticals, Inc. (company) — Registrant
- February 20, 2024 (date) — Date of earliest event reported
- Delaware (company) — State of incorporation
- 399 Thornall Street, First Floor Edison, NJ 08837 (company) — Principal executive offices
- 001-36856 (company) — Commission File Number
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 20, 2024.
What is the full name of the registrant company?
The full name of the registrant company is Hepion Pharmaceuticals, Inc.
What specific items were reported in this 8-K filing?
The 8-K filing reported on the Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; and Compensatory Arrangements of Certain Officers.
In which state is Hepion Pharmaceuticals, Inc. incorporated?
Hepion Pharmaceuticals, Inc. is incorporated in Delaware.
What is the business address of Hepion Pharmaceuticals, Inc.?
The business address of Hepion Pharmaceuticals, Inc. is 399 Thornall Street, First Floor, Edison, NJ 08837.
Filing Stats: 402 words · 2 min read · ~1 pages · Grade level 13.1 · Accepted 2024-02-20 16:15:40
Filing Documents
- form8-k.htm (8-K) — 33KB
- 0001493152-24-007222.txt ( ) — 203KB
- hepa-20240220.xsd (EX-101.SCH) — 3KB
- hepa-20240220_lab.xml (EX-101.LAB) — 33KB
- hepa-20240220_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 Hepion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36856 46-2783806 (State or other jurisdiction (Commission IRS Employer of incorporation or organization) File Number) Identification No.) 399 Thornall Street , First Floor Edison , NJ 08837 (Address of principal executive offices) Registrant's telephone number, including area code: (732) 902-4000 (Former name or former address, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Title of each class: Trading Symbol(s) Name of each exchange on which registered: Common Stock HEPA Nasdaq Capital Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On February 20, 2024, Dr. Gary Jacob resigned from the Board of Directors of Hepion Pharmaceuticals, Inc. (the "Company") for personal reasons. Dr. Jacob was Chairman of the Company and the Board of Directors appointed John Brancaccio as Chairman. -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 20, 2024 HEPION PHARMACEUTICALS, INC. By: /s/ John Cavan John Cavan Interim Chief Executive Officer and Chief Financial Officer -3-